estudiomrgreen
The beginning of a new era

PROTEOMA

It is a Biotechnological Institute in Regenerative Medicine and Advanced Therapies

The word “proteome” proceeds from the expression “proteins expressed from a genome”.

What do we do at PROTEOMA?

PROTEOMA is created with the objective to substantially enhance biotechnological tools, Molecular Biology, Cellular Biology and pharmacology in Biomedicine, to give vital information in a clinical case regarding the diagnoses and treatment on a wide spectrum of neurodegenerative, inflammatory, immune and autoimmune, neoplastic, aging diseases, etc., influencing in the molecular diagnosis and advance therapies (nanobiological) for a personalized medicine. It’s a multidisciplinary team composed by doctors, chemical engineers, biochemists, and pharmacological biologists. Our team has the proved experience in both basic and translational experience, as well as the industry, and has developed an array proteomic test based on biotechnology, allowing a registration of implicated markers in the aforementioned diseases, and provides the physicians a deep knowledge of the pathological condition in the patient on a molecular level, and based on it, the proposal of new nanobiological therapies, just as new therapies for control, improvement and resolution of different pathologies.

CV

Dr. Ernesto Romero Lopez, with over 20 years of experience, is a leading pioneer in stem cell and immunotherapy technology. He holds a Bachelor of Science in General Medicine from Universidad Autónoma de Nayarit, Mexico, and a Master of Science in Regenerative Medicine from Universidad Catolica de Murcia, Madrid, Spain. After his training at the esteemed Nordic University, Dr. Lopez now serves as a stem cell specialist at Immunotherapy Regenerative Medicine in Puerto Vallarta, Mexico.

 

He has devoted two decades to successfully treating patients with stem cell treatments in South America and Europe. As a passionate advocate of biotechnological research, he founded the Bioplenum S.A de C.V institute. His research focuses on the application of mesenchymal stem cells for treating various autoimmune and chronic degenerative diseases.

Doctor Ernesto Romero Lopez - expert in regenerative medicine

CV

RAÚL ROSALES IBÁÑEZ
Doctor of Science in Tissue Engineering in Medicine and Dentistry

 

Dental Surgeon with a PhD in Tissue Engineering in Medicine and Dentistry, specialized in biocompatibility assessments. Integral part of the Tissue Engineering Laboratory, contributing significant advancements in the field of oral health.

CV

Brief CV Dr. Sinforiano J. Posadas: Bachelor of Chemistry and PhD in Biochemistry and Molecular Pathology (Summa Cum Laude by Unanimity). Extensive record of publications in high impact journals in the field of immunology / allergology, aging, hormones, cancer, vaccines, neurodegeneration, microbiology, some of them the best worldwide in their area and also Editor’s Choice, with an H index of 16 and more than 1000 citations to his works. More than 100 Communications, lectures, oral presentations to international and national congresses of different scientific / medical societies. Director and Principal Investigator and co-investigator in numerous projects at the national and international level, both in regional and national programs (Ministry of Science / Universities and FIS Health Research Fund / Carlos III Institute), Europeos Feder, Horizonte, Biomed. Researcher FullBright / MEC and Juan de La Cierva, with postdoctoral stays in Switzerland, Rome, London and UCLA. Director of R&D in the Biotech industry for more than 6 years. Member of various prestigious scientific and evaluation committees: FIS, ANEP, EQA, American Society of Physiology, American Academy of Asthma, Allergy and Immunology, European Allergy and Clinical Immnunology, etc … International award / gold medal in the International Invention Hall / patents in Geneva 2019. Currently developing new advanced therapies, consulting, personalized molecular diagnosis and prevention.

The tendency is towards a personalized medicine according to the Chemistry Nobel Prize. 

Winner of the Nobel Price, Aaron Ciechanover: the revolution towards personalized medicine. Published: Tuesday, June 2nd, 2019 19:36

  • To Aaron Ciechanover, personalized medicine is a paradigm change in relation to how we understand the treatments, and he calls it The Medicine’s Third Revolution.
  • We must propel [the developing] of personalized medicine. It will be an specific treatment, it will cure more people, it will have less side effects.
Aaron_Ciechanover-1

Aaron Ciechanover

PROTEOMA

WHAT WE OFFER

Advance in personalized medicine

WHAT IS PERSONALIZED MEDICINE?

The type of medicine which uses information stored in genes, proteins and the environment of a person to prevent, diagnose and treat a disease.

PROTEOMA

The word «PROTEOME» comes from the expresion “proteins expressed from a genome”. It reffers to a complex composition of proteins expressed and modified by a specific cell, tissue or organ at a certain moment under determine conditions. The proteome constantly changes in response to a series of environmental, intracellular and extracellular signals, health or sickness, cellular developing phase and the effects of treatments.

We designed a new integral method for disease treating in personalized Biomolecular Medicine.

BOMLECULES WE ANALYZE

We obtain a large amount of data to design the therapeutic intervention, growth factors, adhesion molecules, homing cytokines and chemokines, immunological factors, TH1-TH2-TREG-TEH17, cytotoxicity and molecular stress, tumoral progression, metastasis and invasion markers, and anti-tumor factors.

BIOMOLECULAR ANALYSIS

A BIG PROGRESS IN PERSONALIZED MEDICINE

WHEN IS IT INDICATED?

  • PREVENTIION IN MEDICINE
  • WHEN THERE IS GENETIC BACKGROUND IN AUTOIMMUNE DISEASES, CRONICAL-DEGENERATIVE DISEASES, NEOPLASTIC CONDITIONS OR CANCER, ETC.
  • IN GENERAL, WHEN WE WANT TO PREVENT ANY PATHOLOGY BEFORE THE DISEASE MANIFESTS
  • TUMORAL OR CANCER PROCESSES
  • INFLAMMATORY PROCESSES
  • DEGENERATIVES
    • NEUROLOGICAL (PARKINSON, ALZHEIMER, ECT.)
    • ARTICULAR
    • MUSCULOTENDINOUS
  • AUTOIMMUNE
    • ARTHRITIS
    • LUPUS
    • ASTHMA
    • ALS
    • PARKINSON’S
    • ALZHEIMER’S
    • SCLEROSIS
    • ETC.

WHAT IS THE NOVELTY?

IF THEY ARE NOT THE ONLY EXPLORABLE PROTEOMIC PARAMETERS

WHAT IS THE NOVELTY?

“Grouping/selection of exploratory parameters and the connection between them that allows the most efficient interpretation of the patient’s health status.

AND AFTERWARDS, WHAT TREATMENT?

Initially, the only possible way of therapeutic intervention was MONOCLONAL ANTIBODIES, assuming all the innate side effects involved.

Due to the lack of noble medication, our project has gathered a team of experts from different European and American universities, with the goal to develop magistral nanotherapeutic formulas, able to modulate each of the targeted molecules through control of their metabolic pathways, Thus, PROTEOMA was born.

DIFERENCES

PERSONALIZED NANOBIOLOGICAL THERAPY

  • ARTESANAL FABRICATION
  • PERSONALIZED PRODUCT (SPECIALY CREATED FOR THE PATIENT’S REQUIREMENTS, FOR IT IS NOT THE SAME MEDICATION OR THE SAME DOSES FOR EVERYBODY)
  • GOOD TOLERANCE (MINIMAL OR NO SIDE EFFECTS)
  • ACTION OVER SEVERAL ALTERED MOLECULES, IN SEARCH FOR BALANCE.

ALOPATIC MEDICINE

  • INDUSTRIAL FABRICATION (THE SAME MEDICATION AND SAME DOSES FOR EVERYBODY)
  • ACTS ONLY OVER ONE THERAPEUTIC TARGET
  • FRECUENT AND, SOMETIMES, INTENSE SIDE EFFECTS
  • CRONIC USE, AFFECTING THE PATIENT IN THE FUTURE.

IMAGEN DIAGRAMA

We base our nanobiological treatments on “pathways” implicated in the target molecules for new therapies.

 
PROTEOMA

WHAT DO WE ANALIZE?

  • VEGF (VASCULAR ENDOTELIAL GROWTH FACTOR)
  • A POTENT INDUCTOR IN THE FORMATION OF BLOOD VESSELS DURING THE EMBRYONIC DEVELOPING (VASCULOGÉNESIS) AND IN THE FORMATION OF NEW BLOOD VESELS IN THE ADULT (ANGIOGENESIS).
  • PROMOTES ANGIOGENESIS IN THE PROCESSES OF CRONIC INFLAMMATION, SCARING AND TUMORS
  • IT ALSO REGULATES THE FORMATION OF NEW BLOOD VESSELS IN PATHOLOGIES LIKE REUMATHOID ARTHRITIS, OSTEOARTHRITIS, DIABETES AND MACULAR DEGENERATION RELATED TO AGING.
  • HIGH LEVELS OF THIS FACTOR ARE RELATED TO THE POEMS SINDROME (POLI-NEUROPATHY, ORGANOMEGALY, ENDOCRINOPATHY, M PROTEIN, SKIN CHANGES). IT IS ALSO A MARKER FOR THERAPY RESPONSE.
  • VEGF IS ALSO IMPORTANT IN DIABETIC RETINOPATHY.
  • VEGF IS RELATED TO A POOR PROGNOSIS IN CANCER.
  • FGF (FIBROBLAST GROWTH FACTOR)
  • GROTH FACTOR WHICH INCREASES THE RANGE OF MITOSIS ACTIVITY AND DNA SYNTHESIS, EASING THE PROLIFERATION FOR DIFERENT PRECURSOR CELLS, SUCH AS CHONDROBLAST, COLLAGENBLAST, OSTEOBLAST, ETC., WHICH FORM FIBER, UNION AND SUPPORT TISSUES IN THE BODY
  • THIS FACTOR IS RELATED TO TUMORAL ANFIOFENESIS IN ONCOGENIC PROCESSES.
  • FGF CONTRIBUTE TO DIFFERENT TYPES OF RESPONSES, LIKE CICATRIZATION OF WOUNDS, HEMATOPOYESIS, ANGIOGENESIS OR EMBRYONIC DEVELOPMENT.
  • BDNF (BRAIN-DERIVED NEUROTROPHIC FACTOR).
  • IT’S A PROTEIN WHICH ACTS AS GROWTH FACTOR IN THE FAMILY OF NEUROTROPHINS ASSOCIATED TO NERVOUS GROWTH FAVTOR (NGF)
  • THESE NEUROTROPHINS ARE LOCATED INT HE BRAIN AND PERIPHEREAL TISSUE.
  • BDNF IS A POLIPEPTIDIC FACTOR THAT BONDS AND ACTIVATES THE TYROSINE KINASE RECEPTOR TRKB. IT IS IMPORTANT TO THE MOTOR NEURONS SURVIVAL AND THE HIPPOCAMPUS.
  • IMPORTANT MARKER FOR NEUROLOGICAL STRESS.
  • HAS AN IMPORTANT ROLE IN PLASTICITY PROCESSES AND NERVOUS SYSTEM DEVELOPING.
  • GRANZIMES ARE A FAMILY OF SERINE PROTEASES, CONTAINED IN THE CYTOTOXIC GRANULES AND NATURAL KILLER CELLS (NK) IN INNATE AND ADAPTATIVE IMMUNITY.
  • IT’S MAIN ROLE IS TO INDUCE CELL DEATH, TO ELIMINATE CELLS INFECTED WITH VIRUSES AND TUMORAL CELLS.
  • THEY SEEM TO ALSO HAVE A ROLE IN THE REGULATION OF IMMUNE RESPONSE – CONTROLING THE SURVIVAL OF ACTIVATED T LYMPHOCITES-
  • THEY MAY INDUCE INFLAMMATION OVER EXTRACELULAR SUSTRATES.
  • GRANZIME A CAN BE FOUND ON HIGH LEVELS IN PATIENTS WITH INFECTIOUS DESEASES AND/OR PRO-INFLAMMATORY STAGES.
  • GRANZIME B
  • CAN CREATE AUTO-ANTIGENS AND CAUSE AUTOIMMUNE DISEASES
  • THE DESTRUCTION OF B CELLS IN THE PANCREATIC ISLETS IS MEDIATED BY T LYMPHOCITES AND GRANZIME B, WHICH CONTRIBUTE TU TYPE 1 DIABETES.
  • MAY MEDIATE CELL DEATH AFTER A SPINAL CORD INJURY
  • IT IS FOUND IN HIGH LEVELS IN RHEUMATOID ARTHRITIS, COPD AND ASTHMA.
  • GRANZYME B MAY ALSO KILL MELANOCITES, CAUSING SKIN CONDITIONS (CONTACT DERMATITIS, SCLEROTIC LICHEN AND LICHEN PLANE, AND HAIR LOSS!
  • IL-1Β.
  • PROINFLAMMATORY, PYROGENIC AND ACTIVATOR OF HELPER CELLS
  • INDUCED BY LIBERATION OF HISTAMINE FROM MASTOCITES, CAUSING VASODILATION AND LOCAL INFLAMMATION SIGNS.
  • CHEMOTACTIC ACTIVITY OVER GRANULOCITES: NEUTROPHILES, EOSINOPHILS AND BASOPHILS.
  • PYROGENIC EFFECT, CAUSING FEVER DUE TO RELEASE OF PROSTAGLANDINES. ALING IL-6, CAUSES RISING OF HEPATIC PROTEINS OF ACCUTE PHASE (I.E. FIBRINOGEN AND C REATIVE PROTEIN)
  • ACTS OVER THE CENTRAL NERVOUS SYSTEM, INDUCING SLEEP AND ANOREXIA
  • IFN-Γ THE GAMMA INTERFERON
  • A TYPE OF CYTOKIN PRODUCED BY T CD4+ LYMPHOCITES AND NATURAL KILLERS (NK), WHOSE MOST IMPORTANT FUNCTION IS: ACTIVATION OF MACROPHAGES, WITH INCREASE ON THEIR PHACOGYTIC ABILITY, IN BOTH INNATE AND ADAPTATIVE IMMUNITARY RESPONSES
  • INTERVENES IN RECRUITING MONOCYTES FROM CIRCULATION
  • POWERFUL ANTIMICROBIAL ACTIVITY
  • STIMULATES CD8 LYMPHOCITES AND NK TOWARDS INFECTED CELLS
  • TNF-Α (TUMORAL NECROSIS FACTOR ALPHA)
  • CELLULAR SIGNALING PROTEIN (CYTOKINE), INVOLVED IN ACCUTE PHASE SYSTEMATICAL INFLAMMATION
  • PRODUCED BY ACTIVATED MACROPHAGES AND MANY OTHER TYPS OF CELLS (CD4+ LYMPHOCITES, NK CELLS, NEUTROPHILES, MASTOCITES, EOSINOPHILS AND NEURONS)
  • IT’S MAIN FUNCTION IS REGULATING CELLS IN CHARGE OF IL-1 & IL-6 PRODUCTION.
  • TNF, AS AN ENDOGENOUS PYROGEN, IS CAPABLE OF INDUCING FEVER, CELL DEATH, PRO-APOPTOSIS, CAQUEXIA, INFLAMMATION AND INHIBIT TUMORAL GENESIS, VIRAL REPLICATION AND RESPOND TO SEPSIS THROUGH T CELLS.
  • THE LACK OF REGULATION OF TNF PRODUCTION HAS BEEN INVOLVED WITH A VARIETY OF HUMAN CONDITIONS, INCLUDING ALZHEIMER’S, CANCER, MAJOR DEPRESSION, PSORIASIS AND INFLAMMATORY BOWEL DISEASE (IBD).
  • IL-4 (INTERLEUKIN 4)
  • GLUCOPROTEIN CYTOKIN
  • PRODUCED BY Th2 CELLS, BASOPHILS, MASTOCYTES AND ACTIVATED EOSINOPHILS (CELLS INVOLVED IN ALLERGIC REACTIONS)
  • INFLAMMATORY REACTION WHEN BLOCKING IL-1, TNF ALPHA, IL-6 AND MACROPHAGES INFLAMMATORY PROTEIN SYNTHESIS.
  • INVOLVED IN THE REGULATION OF THE IMMUNE SYSTEM
  • PROMOTES THE DIFFERENTIATION IN Th2 AND DIFFERENTIATION OF B LYMPHOCITES.
  • INHIBITS APOPTOSIS.
  • IMPORTANT ROLE IN ASTHMA, ATOPIC DERMATITIS AND ANAPHYLAXIS.
  •  
  • IL-4 (INTERLEUKIN 4)
  • GLOCUPROTEIN CYTOKIN
  • PRODUCED BY Th2 CELLS, BASOPHILS, MASTOCYTES AND ACTIVATED EOSINOPHILS (CELLS INVOLVED IN ALLERGIC REACTIONS)
  • INFLAMMATORY ACTIVITY WHEN BLOCKING IL-1, TNF ALPHA, IL-6 AND MACROPHAGES INFLAMMATORY PROTEIN SYNTHESIS.
  • INVOLVED IN REGULATION OF THE IMMUNE SYSTEM
  • PROMOTES DIFFERENTIATION IN Th2 AND DIFFERENTIATION OF B LYMPHOCITES
  • INHIBITS APOPTOSIS
  • IMPORTANT ROLE IN ASTHMA, ATOPIC DERMATITIS AN ANAPHYLAXIS
  • IL-6 (INTERLEUKIN-6)
  • GLUCOPROTEÍN RELEASED FROM MACROPHAGES, T CELLS, ENDOTELIAL CELLS AND FIBROBLASTS.
  • ITS RELEASE IS INDUCED BY IL-1 AND INCREASES IN RESPONSE TO TNF ALPHA.
  • IT IS A CYTOKINE WITH ANTIINFLAMATORY AND PROINFLAMMATORY ACTIVITY. IN AUTOIMMUNITY AND/OR CRONIC INFLAMMATION,THEY GET WORSE. IT IS AN ENDOGENOUS PYROGEN WHICH STIMULATES THE ACTH PRODUCTION AT THE HYPOPHISIS.
  • IT IS INVOLVED IN THE PRODUCTION OF IMMUNOGLOBULINS, DIFFERENTIATION BETIEN LYMPHOCITES B, ACTIVATES CYTOTOXIC T LYMPHOCYTES, PLASMA CELLS, MODULATES HEMATOPOYESIS AND IS RESPONSIBLE (ALONG IL-4) OF THE SYNTESIS OF ACCUTE PHASE PROTEINS IN ACCUTE HEPATIC PHASE, SPECIALY FIBRINOGEN.
  • IL-6, ALONG IL-1, ACT AS ACCUTE PHASE INFLAMMATORY PROTEINS.
  • IL-10 (INTERLEUKIN-10)
  • PRODUCED BY REGULATOR T LYMPHOCITES, ALONG TGF-B
  • ALSO KNOWN AS CYTOKIN SINTESIS INHIBITOR FACTOR (CSIF), CAPABLE OF INHIBITING PROINFLAMATORY CYTOKIN SYNTHESIS BY T LYMPHOCITES AND MACROPHAGES
  • ANTIINFLAMMATORY AND IMMUNOREGULATOR PROPERTIES
  • ITS PRESENCE HAS BEEN PROVED IN HUMAN ATEROSCLEROTIC PLATES, OBSERVING, IN EXPERIMENTAL STUDIES, THAT LOW LEVELS OF IL-10 FAVOR THE DEVELOPMENT OF MORE EXTENSE ATEROSCLEROTIC LEIONS AND, MORPHOLOGICALY, MORE UNSTABLE.
  • IL-17 (INTERLEUKIN 17). FAMILY OF CYTOKINES PRODUCED BY COOPERATIVE T LYMPHOCITES OR TH17
  • IL-17A PARTICIPATES IN AUTOIMMUNE PROCESSES, INFLAMMATION AND IMMUNITY.
  • IT FAVOURS INFLAMMATORY PROESSES, MAINLY OVER MIELOID CELLS AND MESENCHIMAL CELLS. INDUCES THE EXPRESSION N OTHER SUBSTANCES, AMONG WHICH WE FIND THE GRANULOCYTE COLONY STIMULATING FACTOR, AND INTERLEUKIN IL-6 (IL6).
  • LIF (LEUKEMIA INHIBITOR FACTOR)
  • CELL COMMUNICATION MEDIATIOR WITH A WIDE RANGE OF BIOLOGICAL ACTIVITIES, INCLUDING CELL DIFFERENTIATION, CELL GROWTH AND PROLIFERATION, CELL TROPHISM AND ANTI-APOPTOSIS EFFECT, CELL PROTECTION ON DIFFERENT TYPES OF CELLS AND TISSUES, REGULATOR IN ENERGY AND BONE METABOLISM, NEURAL DEVELOPING, EMBRYOGENESIS, TISSUE REPAIRING AND REMODELING, INFLAMMATION MDULATOR.
  • IL-6 FAMILY // TIROSIN-KINASE ACTION. DUE TO ITS PLEIOTROPIC ATIVITIES, IT IS KEY IN PATHOLOGICAL EVENTS RELATED TO SEVERAL DISORDERS.
  • IN CANCER, IT HAS SHOWN TO BE A PRO-NEOPLASIC AXIS AMONG BREAST, PROSTATE, CORTICOTROPINE ADENOHYPOPHISIS, LUNG AND SKIN CANCER.
  • PRODUCED BY A WIDE RANGE OF CANCER CELL LINES AND PRIMARY NEOPLASMS; ITS ACTION IN BONE METASTASIS IS CLEAR, DUE TO THE CANCER CELLS PRODUCING ÑOF, WHICH ACTS OVER OSTEOCLASTS, STIMULATING THE INVASIV AND OSTEORESORTIVE PROCESS.
  • PD-1 / PDL-1
  • INHIBITOR OF IMMUNITARY CONTROL POINTS.
  • PROTEINS OF CONTROL POINTS, SUCH AS PDL1 (IN TUMORAL CELLS) AND PD-1 (IN T CELLS), HELP TO MANTAIN THE CONTROL ON IMMUNITARY REACTIONS. THE BONDING OF PD-L1 TO PD-1 STOPS THE T CELL FROM DESTROYING THE TUMORAL CELLS IN THE BODY
  • BLOCKING THE PD-1/PDL-1 BONDTHROUGH A IMMUNITARY CONTROL POINT INHIBITOR (ANTI-PDL-1 OR ANTI-PD-1) ALLOS THE T CELLS TO DESTROY TUMORAL CELLS.

CD155. WEAKLY EXPRESSED IN SEVERAL NORMAL HUMAN TISSUES, BUR FRECUENTLY OVERLY-EXPRESSED IN MALIGNANT HUMAN TUMORS.

THE OVER-EXPRESSION OF CD155 PROMOTES THE INVATION AND MIGRATION OF TUMORAL CELLS.

HELPS TUMORAL PROGRESSION AND BAD PROGNOSIS.

CD155 MAY BE CONSIDERED AS A MAIN OBJECTIVE FOR TUMORS OVER-EXPRESSIONG CD144.

IT HAS BEEN PROVED THAT LEVELS OF CD155 WERE SIGNIFICANTLY HIGHER IN SERUMS OF 262 PATIENTS WITH LUNG, GASTRIC, BREAST AND GYNECOLOGICAL CANCER THAN THE SERUM OF HEALTHY DONORS.

ARGINASE ENZYME HAS A SPECIAL RELEVANCE IN THE IMMUNE RESPONSE WHEN COMPETING FOR THE L-ARGNININE WITH ANOTHER ENZIME, THE INDUCING NITRIC-OXIGEN SYNTHETASE.

We obtain an individual proteomic molecular registration, which tells us about the molecular status of the sick or health individual, its functionality, its relation with the pathological state and also how to prevent diseases and other therapeutic interventions.

New Treatments

PROTEOMA

We base our nanobiological treatments in “pathways” involved in the target molecules for the new therapies

New products
  • Specific immunoenhancing serum against borrelia antigen. Indicated in Lyme disease.
  • Neuroimmunodulatory serum for neurological disorders type TEA and derivatives.
  • Neuroimmunodulatory serum for neurological disorders type TEA and derivatives.
  • NK cell activating immunoenhancing serum, indicated in neo processes, chronic viral and bacterial infections.
  • Anti-inflammatory serum indicated in patients using PRP. Combined with it, it has excellent results. Indicated in patients with joint, muscle and bone injuries, as well as in hair transplantation.
  • Immunomodulatory serum indicated in autoimmune and neurodegenerative disorders such as Alzheimer’s, Parkinson’s, ALS. Tb is applied as an anti-aging enhancer.

C/La Gitanilla n# 17, Promalaga I+D 29004 . Malaga. España